Clinical Study Of Buzhong Yiqi Decoction Combined With FOLFIRI Chemotherapy In The Treatment Of Advanced Colorectal Cancer

Purpose:Patients diagnosed with advanced colorectal cancer who were to be treated with FOLFIRI chemotherapy were included in the case study and will be divided randomly into two groups including:a obsversion group and a control group.Both groups were evaluated for benefits before and after treatment.Compare,analyze and evaluate the advantages and feasibility of Buzhong Yiqi Decoction plus orally combined with FOLFIRI chemotherapy treating advanced colorectal cancer,in order to provide valuable experience for clinical treatment of advanced colorectal cancer.Methods:Fifty-two patients with advanced colorectal cancer who were scheduled to receive FOLFIRI chemotherapy were randomly divided into 2 groups.It is the final combination which comes to that there will be 27 patients being put in the treatment group(n=27)and the other 25 patients will go to the control group(n=25).The control group received FOLFIRI chemotherapy alone,while the treatment group received FOLFIRI chemotherapy on the basis of FOLFIRI chemotherapy,and the decoction of Buzhong Yiqi Decoction plus orally was given at the same time.The treatment took 14 days as a course and two courses as 1 After completing two consecutive cycles of treatment,the two groups were evaluated and compared with each other.The evaluation items were:short-term efficacy,TCM symptom score,quality of life score,occurrence and severity of toxic and side effects,tumor indicators carcinoembryonic antigen(CEA),sugar antigens 19-9(CA19-9),carbohydrate antigen 125(CA125),abnormal sugar chain glycoprotein(TAP),and immune indicators(CD3,CD4,CD8,CD4/CD8 in T cell subsets).Carefully track,collect,record,and organize patient data.After completing 2 cycles of treatment,and record the data again in detail,the obtained data is classified into groups and entered into the EXCEL form for screening.According to the different data attributes,different categories of data are separately collected Move into SPSS 22.0 software for statistical calculation.Outcomes:1.Short-term efficacy evaluation of solid tumors:After completing two cycles of treatment,there was no significant difference in the objective reduction rate of solid tumors between the two groups.The results were:RR in the treatment group:25.9%,DCR:81.5%;RR in the control group:24%,DCR:76%.The above results show that the curative effect of the treatment group is still slightly superior to the control group,but the difference is not statistically significant(P>0.05),indicating that the FOLFIRI regimen has a poor effect on the shrinkage rate of advanced colorectal cancer.Using Buzhong Yiqi Decoction may have a slight effect.2.TCM Syndrome Improvement Evaluation:The TCM symptoms of the two groups of patients were improved compared with those before treatment,of which the group of oral Buzhong Yiqi Decoction plus or minus group had outstanding effects.Results:The total effective rate(significant efficiency+effective rate)in the treatment group was 81.5%,and the total effective rate in the control group was 56%.Compared with the two groups,there was statistical significance(P<0.05).It can be seen that the oral Buzhong Yiqi Decoction plus or minus group can be more effective and greatly improve the Chinese medicine symptoms of patients.3.In terms of quality of life scores,the quality of life scores of the treatment group after treatment were significantly improved compared with the previous ones,and the difference was significant(P<0.05).However,the patients in the control group had no significant improvement in quality of life after treatment.The statistical difference shows that the treatment of advanced colorectal cancer with FOLFIRI chemotherapy and oral supplementation of Buzhong Yiqi Decoction can effectively alleviate various discomforts during the treatment and improve the quality of life of patients.4.In terms of toxic and side effects:After completing two consecutive cycles of treatment,the general condition of the patients in the treatment group and the control group was excellent.During the course of treatment,no serious adverse reactions occurred in the two groups of patients.However,the two groups of patients showed varying degrees of treatment-related side effects,and the relevant symptoms were mainly concentrated in the hematological toxicity of peripheral blood leukocytes and the absolute value of neutrophils,gastrointestinal side effects such as nausea and vomiting,diarrhea and constipation.In terms of response,7 patients(25.9%)with diarrhea/constipation symptoms in the treatment group,5 patients(18.5%)had only mild symptoms of nausea and vomiting,and 11 patients(40.7%)had a decrease in the number of bone marrow-suppressed white blood cells.There were 9 cases(33.3%)of anemia,and 12 cases(44.4%)had abnormal liver function indexes.In the control group,15 patients(60.0%)had diarrhea/constipation symptoms and 2(8.0%)had severe symptoms,and 11(44.0%)had nausea and vomiting symptoms.In terms of bone marrow suppression,the number of white blood cells decreased.There were 13 cases(52.0%)and 9 cases(36.0%)of anemia.In terms of liver damage,12 cases(48.0%)had abnormal liver function indicators.Compared with the control group,the treatment group can reduce the probability of nausea,vomiting,diarrhea/constipation,and the difference is obvious and statistically significant(P<0.05).This means that,compared with patients using FOLFIRI chemotherapy alone,oral Buzhong Yiqi Decoction can significantly reduce the chance of intestinal side effects such as diarrhea/constipation,which further confirms the treatment of Buzhong Yiqi Decoction combined with FOLFIRI chemotherapy in the late stage.The safety and effectiveness of colorectal cancer.5.In terms of tumor indicators:after 2 consecutive cycles of treatment,the tumor indicators observed in the treatment group and the control group CEA,CA125,CA19-9,TAP,etc.all decreased compared with before treatment,but the decline of CEA and CA19-9 was small,compared with The difference before treatment was not obvious and had no statistical significance(P>0.05).However,in terms of CA125 and TAP indicators,the treatment group had a significant decrease after treatment compared to the control group before treatment,with statistical significance(P<0.05).This shows that the use of Buzhong Yiqi Decoction can reduce the tumor index compared with the FOLFIRI plan alone.6.In terms of immune indicators:After two consecutive cycles of treatment in the treatment group and the control group,the immune indicators in the Buzhong Yiqi Decoction group were higher than before,while the immune indicators in the chemotherapy-only group were different to those before treatment.Decline.It can be seen that the Buzhong Yiqi Decoction group can effectively maintain and even improve the immune function of chemotherapy patients.After the combination of traditional Chinese medicine and chemotherapy,the value of the CD3 index in the treatment group increased significantly compared with the previous one,which was statistically significant(P<0.05),while the CD4,CD8,CD4/CD8 and other indicators also increased compared to before treatment,suggesting that the patient’s immune function It improved,but the values were not obvious,and there was no statistical significance(P>0.05).This shows that Buzhong Yiqi Decoction combined with chemotherapy can improve the immune index and improve the immune function of patients.Conclusion:At present,in patients with advanced colorectal cancer,the treatment options are often limited,and the treatment options are not effective.The tumor cells are widely distributed in the patient,the total load is large,and the heart,lung,liver,and kidneys are the main organs.Due to heavy device burden and low tolerance to alternatives,they often face problems such as poor quality of life,heavy psychological burden,poor prognosis,and short survival.This study found that,compared with FOLFIRI chemotherapy alone,the addition of Buzhong Yiqi Decoction plus and minus the prescrption,although there is no obvious advantage in objective clinical efficacy,but can reduce the accompanying symptoms such as nausea and vomiting,diarrhea/constipation after chemotherapy.Occurrence,reduce the patient’s burden of activities in daily life,improve appetite,increase appetite,assist regular living and rest,so as to improve the quality of life of patients,to a certain extent reduce the psychological and economic burden of patients and their families,and can also help reduce Tumor indicators to improve body immunity.